Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 3 1Phase 2/3 1Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Urinary Bladder Neoplasms 5Breast Neoplasms 3Urothelial Cancer 1Ureteral Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Recurrence 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Neoplasm Metastasis 1Locally Advanced or Metastatic Unresectable Urothelial Cancer 1Carcinoma, Transitional Cell 1

Interventions

Gemcitabine 12Mitomycin 11Cisplatin 10Carboplatin 8pembrolizumab 7Docetaxel 4toripalimab 3avelumab 3atezolizumab 3Paclitaxel 3sacituzumab govitecan 2disitamab vedotin 2Taxes 2Specimen Handling 2Platinum 2Magnetic Resonance Spectroscopy 2Injections 21,2-diaminocyclohexaneplatinum II citrate 2vinflunine 1valrubicin 1tislelizumab 1lenvatinib 1eribulin 1epacadostat 1enfortumab vedotin 1durvalumab 1dodecyl maltoside 1Vitamin B 12 1Standard of Care 1Ramucirumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Carcinoma, Transitional Cell × vinflunine × Clear all
NCT00315237 2010-01-07

Phase III Trial of Vinflunine Plus Best Supportive Care vs. Best Supportive Care in Patients With Transitional Cell Carcinoma (TCC) of the Urothelial Tract

Bristol-Myers Squibb

Phase 3 Completed
364 enrolled
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡